HAYWARD, Calif. , Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that an abstract, entitled, "Experience in Complex Outpatient Plastic Surgery Procedures Using Sufentanil Sublingual Tablets" has been accepted for podium presentation at Plastic Surgery: The Meeting 2022, taking place October 27-30, 2022 in Boston, MA.

The abstracts will be presented at the meeting and run from Thursday, October 27, 2022 at 1:30 pm until Sunday, October 30, 2022 at 4:30 pm ET . The time of the podium presentation is currently pending, but will be posted on the Investors/Events section of the AcelRx website once that information becomes available. The presentation will be conducted as in-person event only with no virtual or replay option made available.

About Plastic Surgery: The Meeting 2022

Plastic Surgery: The Meeting brings together plastic surgeons from countries around the globe. This annual event is the premier educational and networking event of the year for both domestic and international plastic surgeons, and is considered to serve as the annual meeting of The American Society of Plastic Surgeons (ASPS). ASPS is the largest plastic surgery specialty organization in the world representing 94% of all board-certified plastic surgeons in the U.S. including more than 11,000 plastic surgeons worldwide. ASPS is considered a global institution and leading authority on cosmetic and reconstructive plastic surgery. The meeting also convenes members of The Plastic Surgery Foundation (PSF), the American Society of Maxillofacial Surgeons (ASMS), and the World Society for Simulation Surgery.

About DSUVIA (sufentanil sublingual tablet), 30 mcg DSUVIA®, known as DZUVEO® in Europe , is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with intravenous (IV) administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator (SDA) by healthcare professionals. Sufentanil is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile, when delivered sublingually, avoids the high peak plasma levels and short duration of action observed with IV administration. DZUVEO has been approved by the European Medicines Agency and AcelRx's European commercialization partner, Aguettant, will market the drug in Europe .

This release is intended for investors only.  For more information, including important safety information and black box warning for DSUVIA, please visit www.DSUVIA.com.

About AcelRx Pharmaceuticals, Inc. AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The Company has one approved product in the U.S., DSUVIA® (sufentanil sublingual tablet, 30 mcg), known as DZUVEO® in Europe , indicated for the management of acute pain severe enough to require an opioid analgesic for adult patients in certified medically supervised healthcare settings, and several product candidates. The product candidates include: Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg), an investigational product in the U.S. being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings; two pre-filled, ready-to-use syringes of ephedrine and phenylephrine licensed for the U.S. from Aguettant; Niyad™, a regional anticoagulant for the extracorporeal circuit; and LTX-608, for the potential treatment of COVID-19, disseminated intravascular coagulation, acute respiratory distress syndrome and acute pancreatitis. DZUVEO is an approved product in Europe .

This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-abstract-acceptance-for-podium-presentation-at-plastic-surgery-the-meeting-2022-301603983.html

CDC revises COVID community ratings for Tri-Cities area.

UNITY Biotechnology Inc (NASDAQ: UBX) shares are skyrocketing after 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325 for diabetic macular edema (DME). DME is a diabetic complication that affects the blood vessels in the back of your eye. At 18 weeks after a single UBX1325 injection, the mean change in BCVA of UBX1325-treated subjects was an increase of 6.1 ETDRS letters, representing an improvement of +5.0 ETDRS letters compared to sham-treated subjects. Related: UNITY Biotech Stock

The study, which was recently published in the journal “Scientific Reports,” found that gait patterns among Japanese children aged 6 to 12 vary from those in other developed countries. Age related variations in lower limb movements while walking were studied by scientists from Nagoya University in Japan. For Japanese children in the 11-12 year age group, the number of steps performed each minute was higher than those in the 6-8 year age group.

Vaxxinity missed out on Operation Warp Speed and the first round of COVID-19 vaccines, but CEO Mei Mei Hu is focused on the second generation and ongoing global needs.

GSK on Friday put out a statement saying there's no link between a withdrawn heartburn medication and cancer, helping to stem a slide in its stock that has wiped out billions of dollars in valuation from leading drugmakers.

The "brain health pandemic" since Covid struck exposed a glaring void: Current depression treatments don't fit many patients' needs. A group of biotech stocks hope to change that.

Though my older child is entering first grade this year, I’ve been packing her lunches for years. As other working parents can attest, many of us start packing lunch before our children can even chew. And then, depending on what school lunch is available, and whether our kids will eat it, we continue to pack lunches. Every. Single. Day.

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

Napping has its benefits, but sleep experts say naps aren't a good fit for everyone. Here's why.

Abbott, leading experts discuss how technology can transform the future of healthcare at Aspen Ideas: Health event.

Get ready for the 'Good Energy Lift.'

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

Tight hips, you say? Join the club.

The 53-year-old actress suffered a severe anoxic brain injury and is being treated at the Grossman Burn Center at West Hills Hospital in California.

The House moved Friday to pass a sweeping climate and health care bill, delivering a long-awaited legislative win to President Biden’s desk for his signature. The White House is preparing to deploy officials across the country to promote the historic action on climate change and lowering prescription drug costs contained in the bill, pitching it…

Only have time to ride on the weekends? That counts, too.

After a UBS analyst's note sparked a two-day plunge in the drug makers, their shares rallied Friday after they said there is no evidence the heartburn drug causes cancer.

Actress Anne Heche has died. The 53-year-old actress was in a devastating car accident on Friday, August 5, that left her in a coma. Her family had issued a statement shortly before her death to inform the public that the “Six Days, Seven Nights” actress was not expected to survive after experiencing a catastrophic brain injury caused […]

4D Molecular Therapeutics Inc (NASDAQ: FDMT) said that in June, the company filed a protocol amendment with the FDA for the ongoing Phase 1/2 trial of 4D-310 for Fabry disease. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. SVB Securities cuts 4D Molecular to Market Perform from Outperform with a price target of $12, down from $28 after the Fabry update. The analyst feels this decision is an

"He told me he thought there was too much drama."View Entire Post ›